Prof. PeptideProf. Peptide

November 22, 2026

Eloralintide Plus Tirzepatide (EloraTZP): 23.3% Weight Loss vs 14.8% on Tirzepatide Alone in Phase 2

At ObesityWeek on November 15, 2026, Eli Lilly presented its phase 2b trial of EloraTZP, its investigational once-weekly amylin agonist eloralintide combined with tirzepatide, alongside new reports from participants. In 367 adults with obesity or overweight and type 2 diabetes, the highest dose pair gave 23.3% weight loss at 48 weeks, against 14.8% on tirzepatide alone and 3.0% on placebo, with more stomach and gut side effects and more people stopping treatment on the combination. The results are company-reported; no peer-reviewed paper has been published.

What Lilly reported

Lilly first reported the trial on September 30, 2026, when the results were presented at the European Association for the Study of Diabetes (EASD) meeting in Milan. At 48 weeks, from an average baseline weight of 232.4 lb (105.4 kg) and A1C of 8.1%:

  • Highest dose pair (eloralintide 9 mg + tirzepatide 15 mg): weight −23.3% (−54.1 lb), A1C −2.9 points.
  • Tirzepatide 15 mg alone: weight −14.8% (−34.4 lb), A1C −2.4 points.
  • Eloralintide alone, best arm (6 mg): weight −12.3% (−28.6 lb), A1C −1.4 points.
  • Placebo: weight −3.0% (−7.0 lb), A1C −0.3 points.

Lilly reports that every combination met the trial’s primary endpoint, percent change in body weight against placebo; the comparisons with tirzepatide or eloralintide alone were secondary endpoints. The figures are the efficacy estimand, as Lilly labels them. Lilly says it will start phase 3 trials of an EloraTZP co-formulation by the end of 2026; in this trial the two drugs were given as separate injections.

Results by dose

Lilly’s table of all nine arms (efficacy estimand, 48 weeks):

ArmWeight changeIn poundsA1C change (points)
Eloralintide 3 mg + tirzepatide 5 mg−13.2%−30.7 lb−2.2%
Eloralintide 6 mg + tirzepatide 5 mg−19.4%−45.1 lb−2.7%
Eloralintide 6 mg + tirzepatide 10 mg−19.9%−46.2 lb−2.6%
Eloralintide 9 mg + tirzepatide 15 mg−23.3%−54.1 lb−2.9%
Tirzepatide 15 mg−14.8%−34.4 lb−2.4%
Eloralintide 3 mg−8.2%−19.1 lb−1.1%
Eloralintide 6 mg−12.3%−28.6 lb−1.4%
Eloralintide 9 mg−11.1%−25.8 lb−1.3%
Placebo−3.0%−7.0 lb−0.3%

Adverse events and discontinuations

Lilly reports that the most common adverse events were stomach and gut effects, generally mild or moderate and mostly during dose escalation, and that they were more frequent with the combination than with eloralintide or tirzepatide alone. The share of participants who stopped treatment because of an adverse event was 10.8% to 27.0% across the EloraTZP arms, 0% to 10.8% on eloralintide alone, 2.9% on tirzepatide alone and 16.7% on placebo. Lilly says its phase 3 trials will use an optimized dose-escalation schedule.

New at ObesityWeek: what participants reported

Lilly’s November 14 release for ObesityWeek (November 14 to 17, Washington, D.C.) repeated the EloraTZP topline, adding that up to 60% of participants no longer met the BMI criteria for obesity and up to 77% reached normal blood sugar levels. A poster of exit interviews from the eloralintide phase 2 program reported that at 48 weeks 74% of participants treated with eloralintide described fewer food cravings, “especially for sugary foods,” 52% less “food noise,” and, among those who drank alcohol at baseline, 41% drinking less. These are participants’ own reports, not measured outcomes.

The trial

NCT06603571 is a double-blind phase 2 trial in 367 adults with obesity or overweight and type 2 diabetes. Its ClinicalTrials.gov record lists ten arms: eloralintide alone at three doses, eloralintide with tirzepatide in five dose pairings, tirzepatide alone and placebo, all by subcutaneous injection; Lilly’s results table reports nine of them. The trial started in September 2024 and was completed in September 2026.

What eloralintide is

Lilly describes eloralintide, formerly LY3841136, as an investigational once-weekly, selective amylin receptor agonist that “has the potential to decrease calorie intake,” with effects “likely mediated by affecting satiety, or the feeling of fullness.” Paired with tirzepatide, a GIP and GLP-1 receptor agonist, it acts on three hormone pathways that, Lilly says, the body releases after eating. The same approach, an amylin-receptor drug with an incretin drug, is behind Novo Nordisk’s CagriSema, which pairs cagrilintide with semaglutide.

Status

Eloralintide is not approved anywhere. Lilly says eloralintide alone is already in phase 3 trials for obesity, in adults with or without type 2 diabetes. Lilly’s other investigational obesity drug, retatrutide, is covered on its profile; in its November 14 release Lilly calls retatrutide “an investigational molecule that cannot be legally sold or marketed for human use.”

Sources

This article is for informational and educational purposes only and does not constitute medical advice. It reports company-announced trial results that have not been peer-reviewed. Eloralintide and retatrutide are investigational and not approved for human use in any jurisdiction.

Checked and updated